Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01859754 · ClinicalTrials.gov registry record
Octagam 5% Versus Comparator Post Marketing Trial
A clinical trial, sponsored by Octapharma.
- Completed
- Registry status
- 623
- Enrollment target
NCT01859754: Completed study, sponsored by Octapharma.
NCT01859754 is a clinical trial that has completed, run by Octapharma. The registered enrollment target is 623 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01859754 has completed, sponsored by Octapharma.
- COMPLETED
- Registry status
- 623 participants
- Enrollment target
Study Summary
Study Design: This is a 2 arm non-interventional trial that will compare the occurrence of adverse drug reactions between Octagam 5% and other marketed IVIG infusion treatments.
Interventions
- BIOLOGICAL Octagam 5%
- BIOLOGICAL Other marketed IVIG product
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 623 participants |
| Start Date | 2013-05-21 |
| Est. Completion | 2019-05-22 |
What the finished NCT01859754 record still lists
NCT01859754 is an observational study that tracks outcomes without assigning an intervention. The registered 623 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 2 interventions - of which Octagam 5% is the first listed.
NCT01859754 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01859754 about?
NCT01859754 is a clinical study titled "Octagam 5% Versus Comparator Post Marketing Trial". Study Design: This is a 2 arm non-interventional trial that will compare the occurrence of adverse drug reactions between Octagam 5% and other marketed IVIG infusion treatments.
What is the current status of trial NCT01859754?
This trial is currently completed. The enrollment target is 623 participants. The study started on 2013-05-21. Estimated completion is 2019-05-22.
What interventions are being tested in trial NCT01859754?
The interventions under investigation include: Octagam 5% (BIOLOGICAL), Other marketed IVIG product (BIOLOGICAL).
Who is sponsoring clinical trial NCT01859754?
This trial is sponsored by Octapharma, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06406049 · 624 participants · NA
Finishing HIV Project
- NCT05349227 · 625 participants · NA
Comprehensive Outcomes for After Cancer Health
- NCT06103864 · 625 participants · Phase 3
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
- NCT06230510 · 625 participants · NA
Milk-Tot Study: Impact of Whole Versus Low-fat Milk on Child Health
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI